Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 144Neoplasms 99Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

Nivolumab 2pembrolizumab 1folfirinox 1durvalumab 1Trastuzumab 1Single Person 1Paclitaxel 1Irinotecan 1IFL protocol 1Folfox protocol 1Docetaxel 1Carboplatin 1((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastroesophageal Adenocarcinoma × Nivolumab × Clear all
NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

University of California, Irvine

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT04021108 2025-06-24

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Weill Medical College of Cornell University

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡